Azitra, Inc.
ATR-12
Netherton syndrome
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for ATR-12 in Netherton syndrome are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Topline data from the Phase 1b trial is anticipated H2 2026.”